首页> 外国专利> PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE.

PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE.

机译:吡唑羧酰胺衍生物作为TAAR调节剂,可用于治疗多种疾病,例如抑郁症,糖尿病和帕金森氏病。

摘要

The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxy; or is pyridine-2, 3 or 4-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxyl; or is pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or is pyrazin-2-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cyano; or is 2,2-difluorobenzo[d][l,3]dioxol-5-yl, or is thiazolyl, optionally substituted by lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, amino or lower alkyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
机译:本发明涉及式(I)的化合物,其中R 1为苯基,任选地被卤素,低级烷基,低级环烷基,低级烷氧基,氰基,被卤素取代的低级烷基,被羟基取代的低级烷基,被卤素或低级烷氧基取代的苯基。被羟基取代的低级烷氧基;或为吡啶-2、3或4-基,其任选地被卤素,低级烷基,低级环烷基,氰基,被卤素取代的低级烷基,被羟基取代的低级烷基,低级烷氧基,被卤素取代的低级烷氧基或被卤素取代的低级烷氧基羟;或为嘧啶-2、4或5-基,其任选地被卤素,低级烷基,低级环烷基,被羟基取代的低级烷基或被卤素取代的低级烷基取代;或者是吡嗪-2-基,任选地被卤素,低级烷基,低级环烷基,被卤素取代的低级烷基,被羟基或氰基取代的低级烷基取代;或为2,2-二氟苯并[d] [1,3]二氧杂-5-基,或为噻唑基,任选地被被卤素取代的低级烷基取代; R 2是氢或低级烷基; R3是氢,氨基或低级烷基; Z为键,-CH 2-或-O-;或其可药用的酸加成盐。现已发现,式I化合物对痕量胺相关受体(TAAR)具有良好的亲和力,特别是对于TAAR1。这些化合物可用于治疗抑郁症,焦虑症,躁郁症,注意力缺陷多动障碍(ADHD),与压力有关的疾病,精神分裂症(例如精神分裂症),神经系统疾病(例如帕金森氏病),神经退行性疾病(例如阿尔茨海默氏病),癫痫,偏头痛,高血压,滥用药物和代谢紊乱,例如饮食失调,糖尿病,糖尿病并发症,肥胖,血脂异常,能量消耗和同化失调,体温稳态失调和失调,睡眠和昼夜节律紊乱以及心血管疾病。

著录项

  • 公开/公告号MX363362B

    专利类型

  • 公开/公告日2019-03-21

    原文格式PDF

  • 申请/专利权人 F. HOFFMANN-LA ROCHE AG;

    申请/专利号MX20150002900

  • 申请日2013-09-11

  • 分类号C07D403/12;A61K31/4155;A61K31/454;A61K31/5377;A61P25;C07D401/12;C07D413/12;C07D413/14;C07D417/14;

  • 国家 MX

  • 入库时间 2022-08-21 12:01:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号